The influence of adequate drug therapy on the clinical symptoms and level of serum amyloid A in patients with chronic obstructive pulmonary disease.
Open Access
- 24 May 2018
- journal article
- research article
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 23 (2(part1)), 36-41
- https://doi.org/10.26641/2307-0404.2018.2(part1).129513
Abstract
The aim of our research was to study the dynamics of the level of SAA in COPD patients in the stable phase of the pathological process against the background of basic therapy. We studied 37 stable COPD patients with II-IV degree of ventilation violations according to the GOLD classification, distributed in two subgroups depending on the adequacy of taking basic therapy. Stable COPD patients, irrespective of the severity of the course of the disease in conditions of inadequate treatment have greater symptom severity, the number of exacerbations over the past year and the level of SAA than patients taking long-term therapy according to COPD severity. Taking therapy corresponding to the severity of the disease within three months by COPD patients helps to reduce the severity of COPD symptoms to the level of these indicators in patients taking adequate therapy for a longer period of time. Treatment of COPD patients which corresponds to the severity of the disease within three months contributes to a significant reduction of SAA level.Keywords
This publication has 4 references indexed in Scilit:
- Personalized medicine and chronic obstructive pulmonary diseaseCurrent Opinion in Pulmonary Medicine, 2017
- Reduced soluble receptor for advanced glycation end-products in COPDEuropean Respiratory Journal, 2010
- Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax, 2004